This company has been marked as potentially delisted and may not be actively trading. Intra-Cellular Therapies (ITCI) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipSustainabilityTrendsBuy This Stock Intra-Cellular Therapies (NASDAQ:ITCI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.60%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$6.41M Get ITCI Insider Trade Alerts Want to know when executives and insiders are buying or selling Intra-Cellular Therapies stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ITCI Insider Buying and Selling by Quarter Intra-Cellular Therapies Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/3/2025Josh GottheimerU.S. Congress Member (D-NJ)Sell$131.87$1,001 - $15,0004/3/2025Gilbert Ray Cisneros, Jr.U.S. Congress Member (D-CA)Sell$131.87$1,001 - $15,0003/24/2025Gilbert Ray Cisneros, Jr.U.S. Congress Member (D-CA)Sell$131.70$1,001 - $15,0003/17/2025Josh GottheimerU.S. Congress Member (D-NJ)Sell$131.45$1,001 - $15,0001/24/2025Josh GottheimerU.S. Congress Member (D-NJ)Sell$127.35$1,001 - $15,00012/4/2024Sharon MatesCEOSell51,000$85.80$4,375,800.00 11/12/2024Michael HalsteadPresidentSell22,869$89.12$2,038,085.28 (Data available from 1/1/2013 forward) ITCI Insider Trading Activity - Frequently Asked Questions Who is on Intra-Cellular Therapies' Insider Roster? The list of insiders at Intra-Cellular Therapies includes Joel S Marcus, Lawrence J. Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates, Suresh K Durgam. Learn more on insiders at ITCI. What percentage of Intra-Cellular Therapies stock is owned by insiders? 2.60% of Intra-Cellular Therapies stock is owned by insiders. Learn more on ITCI's insider holdings. Which Intra-Cellular Therapies insiders have been selling company stock? The following insiders have sold ITCI shares in the last 24 months: Joel S Marcus ($1,808,207.04), Lawrence J. Hineline ($2,468,160.27), Mark Neumann ($3,763,369.71), Michael Halstead ($6,413,908.64), Nostrand Robert L Van ($1,518,200.00), Rory B Riggs ($337,193.34), Sharon Mates ($31,128,581.66), and Suresh K Durgam ($429,312.00). How much insider selling is happening at Intra-Cellular Therapies? Insiders have sold a total of 761,349 Intra-Cellular Therapies shares in the last 24 months for a total of $53,646,071.86 sold. Which members of congress are trading Intra-Cellular Therapies? Josh Gottheimer (D-NJ) and Gilbert Ray Cisneros, Jr. (D-CA) have sold shares of Intra-Cellular Therapies in the last year totaling $40,000. Intra-Cellular Therapies Key ExecutivesDr. Sharon Mates Ph.D. (Age 71)Co-Founder, Chairman & CEO Compensation: $2.23MMr. Michael I. Halstead J.D. (Age 51)President Compensation: $983.65kDr. Suresh K. Durgam M.D. (Age 55)Executive VP & Chief Medical Officer Compensation: $961.84kMr. Mark Neumann (Age 61)EVP & Chief Commercial Officer Compensation: $998.36kDr. Robert E. Davis Ph.D. (Age 73)Senior VP & Chief Scientific Officer Compensation: $646.12kMr. Juan Fernando Sanchez (Age 53)Vice President of Corporate Communications & Investor Relations Compensation: $296.75kMs. Karen Patruno Sheehy Esq. (Age 62)Senior VP & Chief Compliance Officer Dr. Michael OlchaskeySenior VP & Head of Regulatory AffairsMr. John A. BardiSenior VP of Market Access, Policy & Government AffairsDr. Willie R. Earley M.D.Senior VP & Head of Clinical Development More Insider Trading Tools from MarketBeat Related Companies Takeda Pharmaceutical Insider Transactions argenex Insider Transactions BeOne Medicines Insider Transactions Insmed Insider Transactions BioNTech Insider Transactions Teva Pharmaceutical Industries Insider Transactions Genmab A/S Insider Transactions Summit Therapeutics Insider Transactions Viatris Insider Transactions BridgeBio Pharma Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Small Caps That Insiders Are Buying $100 Million Buyback in Upwork Stock Follows a Strong Quarter Insiders Sell These High-Quality Stocks: Why Investors Shouldn’tCoreWeave and Madrigal's Insider Trades Flash Bullish SignalsPalantir Insider Selling: Risk Signal or Normal Activity? This page (NASDAQ:ITCI) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITCI Stock Alerts